Home › NDC Lookup › RxCUI directory › RxCUI 2196894

24 HR upadacitinib 15 MG Extended Release Oral Tablet — RxCUI 2196894

RxNorm drug concept · Semantic clinical drug
RxCUI 2196894 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2196894
Official name24 HR upadacitinib 15 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asupadacitinib 15 MG 24HR Extended Release Oral Tablet
FDA products mapped4
Package NDCs mapped8
Reported Medicaid activity (SDUD)108,976 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Upadacitinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Rinvoq works by blocking overactive signals in your immune system that cause inflammation. Depending on your condition — whether that's rheumatoid arthritis, psoriatic arthritis, e...
  • What exactly is Rinvoq supposed to do for me?
  • You take Rinvoq once a day by mouth. The tablet form can be taken with or without food — a meal won't meaningfully affect how well it works. The oral solution (Rinvoq LQ) is simila...
  • How do I take it — does it matter if I take it with food?
📖 Read our full Upadacitinib guide →

🕸️ Concept Web — How 24 HR upadacitinib 15 MG Extended Release Oral T... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR upadacitinib 15 MG Extended Release Oral Tablet RxCUI 2196894

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Upadacitinib 2196092
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rinvoq 2196895
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Upadacitinib Extended Release Oral Tablet 2196893
    • Upadacitinib Oral Product 2196891
    • Upadacitinib Pill 2196892
    • Upadacitinib Extended Release Oral Tablet [Rinvoq] 2196897
    • Rinvoq Oral Product 2196898
    • Rinvoq Pill 2196899
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Upadacitinib 15 MG SCDC · 2196890
  • Upadacitinib Extended Release Oral Tablet SCDF · 2196893
  • Upadacitinib Oral Product SCDG · 2196891
  • Upadacitinib Pill SCDG · 2196892

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 8 package NDCs
8 package NDCs map to RxCUI 2196894 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-1043-14 14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-1043-14) Rinvoq AbbVie Inc. 2022-03-16
00074-1043-28 28 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-1043-28) Rinvoq AbbVie Inc. 2022-03-16
00074-2306-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-30) Rinvoq AbbVie Inc. 2019-08-16
00074-2306-70 14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2306-70) Rinvoq AbbVie Inc. 2019-08-16
00074-2310-20 14 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2310-20) Rinvoq AbbVie Inc. 2019-08-16
00074-2310-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0074-2310-30) Rinvoq AbbVie Inc. 2019-08-16
00074-2320-01 1 BOTTLE in 1 CARTON (0074-2320-01) / 180 mL in 1 BOTTLE Rinvoq AbbVie Inc. 2024-04-26
00074-2320-70 1 BOTTLE in 1 CARTON (0074-2320-70) / 180 mL in 1 BOTTLE Rinvoq AbbVie Inc. 2024-04-26
Observed labelers: AbbVie Inc. (8) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.